Chemotherapy and Radiation Following Pancreatic Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00660270|
Recruitment Status : Completed
First Posted : April 17, 2008
Last Update Posted : April 23, 2013
To describe the overall survival and disease-free survival in pancreatic cancer patients treated with adjuvant chemoradiation with cisplatin, continuous infusion 5FU and interferon alpha followed by gemcitabine.
To describe the toxicities associated with adjuvant chemoradiation with cisplatin. 5FU and interferon alfa followed by gemcitabine in patients with pancreatic cancers.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Procedure: Pancreatic Surgery Radiation: Radiation therapy Drug: Cisplatin Drug: 5-FU Drug: Alpha-interferon Drug: Gemcitabine||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||53 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial Of Adjuvant Chemoradiation Following Pancreatic Resection For Adenocarcinomas Of The Pancreas Using 3-D Conformal Radiation With Cisplatin, 5FU, And Alpha-Interferon As Radiosensitizing Agents Followed By Gemcitabine|
|Study Start Date :||May 2002|
|Actual Primary Completion Date :||November 2006|
|Actual Study Completion Date :||February 2009|
Experimental: Arm 1
Surgery (pancreaticoduodenectomy, either standard or pylorus-preserving, with either standard or extended lymph node dissection, with or without portal vein resection) should occur at 8 weeks (plus or minus 2, not to exceed 10)
Radiation therapy will occur 8 weeks (plus or minus 2, not to exceed 10) postoperatively. Daily dose of 1.8 Gy five days per week. The first 45 Gy will be given to planning target volume 1. After 45 Gy, portals will be reduced to encompass planning target volume 2. The boost dose will be 5.4 Gy.
Cisplatin IV 25 mg/m2 on days 1, 8, 15, 22, 29, and 36 during radiation.
5-FU CIVI at 175 mg/m2/d on days 1-38 without interruption during radiation.
Alpha-interferon SQ 3,000,000 units on Mondays, Wednesdays, and Fridays during radiation therapy.
Gemcitabine IV 1000 mg/m2 4 weeks after conclusion of radiation (on a 3 weeks on/1 week off schedule) on days 71, 78, 85, 99, 106, and 113.
Procedure: Pancreatic Surgery
Radiation: Radiation therapy
Other Names:Drug: 5-FU
Other Names:Drug: Alpha-interferon Drug: Gemcitabine
Other Name: Gemzar
- To describe the overall survival and disease-free survival [ Time Frame: 2 years ]
- To describe the toxicities associated with adjuvant chemoradiation with cisplatin, 5FU and interferon alfa followed by gemcitabine in patients with pancreatic cancers. [ Time Frame: Week 15 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00660270
|United States, Missouri|
|Washington University School of Medicine|
|St. Louis, Missouri, United States, 63119|
|Principal Investigator:||David Linehan, MD||Washington University School of Medicine|